Clinical-stage biopharmaceutical company Realm Therapeutics has completed enrollment in its Phase 2 study of PR022 - its topical IL-4 / IL-13 inhibitor for the treatment of atopic dermatitis - it announced on Thursday. The AIM-traded firm said the trial was being conducted in the United States, and it continued to expect to report top line results in the third quarter of this year. "This Phase 2 study is designed to demonstrate that PR022, our proprietary topical gel formulation of high ...Den vollständigen Artikel lesen ...